Project Grant R01CA311018
Award Date 8/1/26
Completion Date 7/31/29
Dollars Obligated $2.2M
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, NY 14642, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded Case Western Reserve University $3,778,614 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate transient selective neural inhibition via photobiomodulation (TSNIP) for chronic knee pain treatment. The research integrates optimized TSNIP parameters into the COSMIIC modular platform—an FDA-qualified system already proven safe for electrical stimulation and sensing in...
- The National Institute of Neurological Disorders and Stroke awarded Temple University $2,470,369 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate a cannabidiol (CBD) nanoemulsion formulation, SRIN-009, for treating chemotherapy-induced peripheral neuropathy (CIPN). The project addresses CIPN, a debilitating adverse effect affecting up to 75 percent of patients receiving certain chemotherapy regimens, characterized by pain,...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded The Johns Hopkins University a $2.71 million Project Grant (effective August 6, 2025 through July 31, 2030) under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological mechanisms underlying paclitaxel-induced peripheral neuropathy (PIPN). The award supports research utilizing novel whole dorsal root ganglia (DRG) in vivo imaging technology to monitor sensory...
- The National Institute of Neurological Disorders and Stroke (part of the Department of Health and Human Services National Institutes of Health) awarded Oregon Health & Science University $5.363 million on August 18, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to optimize spinal cord stimulation parameters for pain and itch management. The research investigates how epidural spinal cord stimulation engages dorsal horn circuits, specifically targeting neuropeptide Y...
- The National Institute of Neurological Disorders and Stroke awarded $466,021 to Weill Medical College of Cornell University on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate ACCENT (Acyclovir-Controlled Calcium Entry Neuromodulation Tool), a novel RNA-based platform for selective modulation of L-type voltage-gated calcium channels to treat chronic pain and reduce opioid dependence. The research addresses the clinical problem of...
- The National Institute on Drug Abuse awarded a cooperative agreement totaling $717,986 to Research Foundation For Mental Hygiene, Inc. on May 15, 2026, to test the efficacy of transcutaneous auricular neurostimulation (TAN) in reducing naloxone-precipitated opioid withdrawal symptoms under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a randomized, double-blind, sham-controlled clinical trial examining whether non-invasive TAN stimulation of the vagus and trigeminal...
- The National Institute of Neurological Disorders and Stroke (NINDS), part of the Department of Health and Human Services National Institutes of Health, awarded Case Western Reserve University $189,000 on July 20, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). Case Western Reserve University, through its Office of Research Administration in affiliation with University Hospitals of Cleveland, will conduct a randomized, sham-controlled, parallel-group feasibility trial...
- The National Institute of Neurological Disorders and Stroke awarded the University of Florida $1,497,985 on September 3, 2026, to conduct a randomized clinical trial evaluating wearable focal vibration therapy for diabetic peripheral neuropathy under CFDA 93.279 (Drug Use and Addiction Research Programs). The research will enroll 120 participants with diabetic peripheral neuropathy in an eight-week trial comparing four weeks of wearable focal vibration therapy against sham vibration control. The...
- The National Institute of Neurological Disorders and Stroke awarded the University of Tennessee $475,375 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot a family-based pain intervention for Appalachian breast cancer patients experiencing treatment-related pain during adjuvant endocrine therapy. The Conquering Pain Together (CPT) intervention addresses pain discontinuation as a primary driver of therapy non-adherence in rural Appalachia,...
- The National Institute of Neurological Disorders and Stroke awarded the Regents of the University of Minnesota a cooperative agreement valued at $769,903 on August 1, 2026, to conduct a feasibility and pilot trial of a novel invasive brain stimulation approach for chronic neuropathic pain. The study combines precision functional mapping and individualized neurostimulation targeting the somato-cognitive action network and cingulo-opercular network—two key circuits in pain processing—to address...